Biocartis Group NV Company Description
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology.
Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring.
The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.
It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays.
The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies.
It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform.
The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Country | Belgium |
Founded | 2007 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Employees | 526 |
CEO | Roger Moody |
Contact Details
Address: Generaal de Wittelaan 11 B Mechelen, 2800 Belgium | |
Phone | 32 1 563 26 00 |
Website | biocartisgroupnv.be |
Stock Details
Ticker Symbol | BCART |
Exchange | Euronext Brussels |
Fiscal Year | January - December |
Reporting Currency | EUR |
ISIN Number | BE0974281132 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Roger Moody | Chief Executive Officer |
Piet Houwen | Chief Operating Officer |
George A. Cardoza | Chief Financial Officer and Head of Service Delivery |
Benoit Devogelaere | Chief Technology Officer |
Geert Maertens Ph.D. | Chairman of Scientific Advisory Board and Chief Scientific Officer |
Renate Degrave | Head of IR and Corporate Communications |
Erik Vossenaar Ph.D. | Senior Vice-President of Corporate Development and Strategy |
Susy Spruyt | Head of People and Organization |
Dr. Erwin Sablon | Head of Research & Development and Alliance Management |
Reginald Van Genechten | Head of Manufacturing and Supply Chain |